中华行为医学与脑科学杂志
中華行為醫學與腦科學雜誌
중화행위의학여뇌과학잡지
CHINESE JOURNAL OF BEHAVIORAL MEDICINE AND BRAIN SCIENCE
2014年
2期
107-109
,共3页
田苗%张向萍%张洪涛%修春明%崔广强%迟楠%王云波%汤国太
田苗%張嚮萍%張洪濤%脩春明%崔廣彊%遲楠%王雲波%湯國太
전묘%장향평%장홍도%수춘명%최엄강%지남%왕운파%탕국태
胶质瘤%环氧化酶-2%肿瘤微环境%免疫逃逸
膠質瘤%環氧化酶-2%腫瘤微環境%免疫逃逸
효질류%배양화매-2%종류미배경%면역도일
Gliomas%Cyclooxygenase 2%Tumor microenvironment%Immune escape
目的 探讨选择性环氧化酶-2(cyclooxygenase-2,COX-2)抑制剂塞来昔布(celecoxib)对大鼠脑胶质瘤免疫微环境及生物学行为的影响.方法 建立大鼠脑胶质瘤模型,观察celecoxib治疗后肿瘤大小及大鼠生存期；免疫组化法检测肿瘤组织COX-2、转化生长因子-β(transforming growth factor-beta,TGF-β)、血管内皮生长因子(vascular endothelial growth factor,VEGF)蛋白表达；流式细胞术检测肿瘤微环境CD4+CD25+T细胞亚群数量；酶联免疫法(ELISA)检测大鼠血清中前列环素E2(Prostaglandin E2,PGE2)、白介素-l0(IL-l0)、白介素-12(IL-12)分泌水平.结果 Celecoxib治疗组肿瘤体积明显小于对照组[(103.67±5.54) mm3,(151.60±8.34) mm3,P＜0.01],并可延长大鼠生存期[(42.87± 1.72)d,(26.13± 1.53)d,P＜0.01],肿瘤组织中COX-2、VEGF及TGF-β蛋白的表达均出现下调,其肿瘤微环境中CD4+CD25+T细胞亚群比例明显降低(5.32％,7.84％,P＜0.05).血清中PGE2与IL-10水平明显下降[(223.66±33.79)pg/ml,(344.15±41.09) pg/ml,(98.69± 10.99) pg/ml,(133.37± 13.15) pg/ml,P＜0.01],而IL-12分泌明显增多[(237.20±37.31) pg/ml,(117.90±19.20) pg/ml,P＜0.01].结论 Celecoxib可通过多种途径改善肿瘤局部免疫微环境,从而改变肿瘤的生物学行为,延缓肿瘤发展,并为肿瘤治疗提供良好的基础环境.
目的 探討選擇性環氧化酶-2(cyclooxygenase-2,COX-2)抑製劑塞來昔佈(celecoxib)對大鼠腦膠質瘤免疫微環境及生物學行為的影響.方法 建立大鼠腦膠質瘤模型,觀察celecoxib治療後腫瘤大小及大鼠生存期；免疫組化法檢測腫瘤組織COX-2、轉化生長因子-β(transforming growth factor-beta,TGF-β)、血管內皮生長因子(vascular endothelial growth factor,VEGF)蛋白錶達；流式細胞術檢測腫瘤微環境CD4+CD25+T細胞亞群數量；酶聯免疫法(ELISA)檢測大鼠血清中前列環素E2(Prostaglandin E2,PGE2)、白介素-l0(IL-l0)、白介素-12(IL-12)分泌水平.結果 Celecoxib治療組腫瘤體積明顯小于對照組[(103.67±5.54) mm3,(151.60±8.34) mm3,P＜0.01],併可延長大鼠生存期[(42.87± 1.72)d,(26.13± 1.53)d,P＜0.01],腫瘤組織中COX-2、VEGF及TGF-β蛋白的錶達均齣現下調,其腫瘤微環境中CD4+CD25+T細胞亞群比例明顯降低(5.32％,7.84％,P＜0.05).血清中PGE2與IL-10水平明顯下降[(223.66±33.79)pg/ml,(344.15±41.09) pg/ml,(98.69± 10.99) pg/ml,(133.37± 13.15) pg/ml,P＜0.01],而IL-12分泌明顯增多[(237.20±37.31) pg/ml,(117.90±19.20) pg/ml,P＜0.01].結論 Celecoxib可通過多種途徑改善腫瘤跼部免疫微環境,從而改變腫瘤的生物學行為,延緩腫瘤髮展,併為腫瘤治療提供良好的基礎環境.
목적 탐토선택성배양화매-2(cyclooxygenase-2,COX-2)억제제새래석포(celecoxib)대대서뇌효질류면역미배경급생물학행위적영향.방법 건립대서뇌효질류모형,관찰celecoxib치료후종류대소급대서생존기；면역조화법검측종류조직COX-2、전화생장인자-β(transforming growth factor-beta,TGF-β)、혈관내피생장인자(vascular endothelial growth factor,VEGF)단백표체；류식세포술검측종류미배경CD4+CD25+T세포아군수량；매련면역법(ELISA)검측대서혈청중전렬배소E2(Prostaglandin E2,PGE2)、백개소-l0(IL-l0)、백개소-12(IL-12)분비수평.결과 Celecoxib치료조종류체적명현소우대조조[(103.67±5.54) mm3,(151.60±8.34) mm3,P＜0.01],병가연장대서생존기[(42.87± 1.72)d,(26.13± 1.53)d,P＜0.01],종류조직중COX-2、VEGF급TGF-β단백적표체균출현하조,기종류미배경중CD4+CD25+T세포아군비례명현강저(5.32％,7.84％,P＜0.05).혈청중PGE2여IL-10수평명현하강[(223.66±33.79)pg/ml,(344.15±41.09) pg/ml,(98.69± 10.99) pg/ml,(133.37± 13.15) pg/ml,P＜0.01],이IL-12분비명현증다[(237.20±37.31) pg/ml,(117.90±19.20) pg/ml,P＜0.01].결론 Celecoxib가통과다충도경개선종류국부면역미배경,종이개변종류적생물학행위,연완종류발전,병위종류치료제공량호적기출배경.
Objective To investigate the effect of celecoxib,a selective inhibitor of cyclooxygenase-2 (COX-2),on glioma immune microenvironment and biological action in rat.Methods After treated with celecoxib,tumor volume and survive time were observed in a rat glioma model.COX-2,transforming growth factor-beta (TGF-β) and vascular endothelial growth factor(VEGF) expression in tumor tissue were detected using immunehistory and CD4 + CD25 + T cells was detected by flowcytometry.By using enzyme-linked immunosorbent assay (ELISA),the production of prostaglandin(PGE2),interlukin 10(IL-10) and interlukin 12(IL-12) were detected in rat serum.Results Tumor volume decreased after treated with celecoxib ((103.67±5.54) mm3,(151.60±8.34)mm3,P＜0.01) and survive time of animals were prolonged ((42.87±1.72) d,(26.13±1.53)d,P＜0.01).Expression of COX-2,TGF-β and VEGF in tumor tissue was down regulated after treated with celecoxib and number of CD4+CD25 + T cells were decreased (5.32％,7.84％,P＜ 0.05).PGE2,IL-10 production in serum was obviously decreased by treatment of celecoxib ((223.66±33.79) pg/ml,(344.15±41.09) pg/ml,(98.69± 10.99) pg/ml,(133.37± 13.15) pg/ml,P＜0.01) while the production of IL-12 was increased ((237.20±37.31) pg/ml,(117.90±19.20) pg/ml,P＜0.01).Conclusion Celecoxib may improve the status of immunosuppression of rat glioma by several pass ways and modify tumor biological action.Celecoxib may give a good microenvironment for immunotherapy of gliomas.
